Cytosorbents (CTSO) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$3.2 million.
- Cytosorbents' Income towards Parent Company fell 1452.31% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.4 million, marking a year-over-year increase of 1597.93%. This contributed to the annual value of -$20.7 million for FY2024, which is 2915.81% up from last year.
- Latest data reveals that Cytosorbents reported Income towards Parent Company of -$3.2 million as of Q3 2025, which was down 1452.31% from -$4.2 million recorded in Q2 2025.
- Cytosorbents' Income towards Parent Company's 5-year high stood at -$766126.0 during Q4 2022, with a 5-year trough of -$12.2 million in Q3 2022.
- Moreover, its 5-year median value for Income towards Parent Company was -$6.2 million (2023), whereas its average is -$6.1 million.
- As far as peak fluctuations go, Cytosorbents' Income towards Parent Company crashed by 127327.47% in 2021, and later skyrocketed by 9176.83% in 2022.
- Over the past 5 years, Cytosorbents' Income towards Parent Company (Quarter) stood at -$9.3 million in 2021, then soared by 91.77% to -$766126.0 in 2022, then crashed by 758.12% to -$6.6 million in 2023, then fell by 15.1% to -$7.6 million in 2024, then skyrocketed by 58.11% to -$3.2 million in 2025.
- Its Income towards Parent Company was -$3.2 million in Q3 2025, compared to -$4.2 million in Q2 2025 and -$1.5 million in Q1 2025.